Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ovarian Neoplasms

Free Subscription 03.12.2018 2 BMC Cancer 1 Cancer 1 Cancer Res 7 Gynecol Oncol 1 Int J Cancer 1 Oncogene 2 Oncol Rep 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Cancer

1. LEE IO, Lee JY, Kim HJ, Nam EJ, et al
   Prognostic significance of supradiaphragmatic lymph node metastasis detected by (18)F-FDG PET/CT in advanced epithelial ovarian cancer.
   BMC Cancer. 2018;18:1165.
   PubMed     Text format     Abstract available
   
   
2. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
   Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
   BMC Cancer. 2018;18:1177.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

3. FREY MK, Kopparam RV, Ni Zhou Z, Fields JC, et al
   Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
   Cancer. 2018 Nov 27. doi: 10.1002/cncr.31856.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

4. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
   Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
   Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

5. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
   Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
   Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
   PubMed     Text format     Abstract available
   
   
6. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
   Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
   Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
   PubMed     Text format     Abstract available
   
   
7. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
   Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
   Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
   PubMed     Text format     Abstract available
   
   
8. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
   Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
   Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
   PubMed     Text format     Abstract available
   
   
9. JAVELLANA M, Hoppenot C, Lengyel E
   The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
   Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
   PubMed     Text format     Abstract available
   
   
10. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Text format     Abstract available
    
    
11. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

12. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

13. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

14. MLYNSKA A, Salciuniene G, Zilionyte K, Garberyte S, et al
    Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6886.
    PubMed     Text format     Abstract available
    
    
15. LU DH, Yang J, Gao LK, Min J, et al
    Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6888.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

16. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    PLoS One. 2018;13:e0207319.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: